Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe.
The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 ethyl ester.
Novaliq’s NovaTears therapy combined with Omega-3 works by stabilizing the lipid layer of the tear film, reducing the evaporation of the underlying water phase and supplementing the lipid layer with Omega-3.
The company characterized its NovaTears product as the first lipid layer stabilizer that improves the signs and symptoms in patients with DED without causing vision blurring.
“It is well-known that dry eye disease compromises the lipid layer of the tear film, which, in healthy eyes, protects the tear film against evaporation,” Jerry Cagle, Alcon’s former chief scientific officer and member of Novaliq’s supervisory board, said in prepared remarks. “The addition of Omega-3 fatty acids to an already powerful NovaTears eye drop will provide dry eye patients with additional relief and physiological benefits by stabilizing the lipid layer. This will be a welcome and much-needed addition to ophthalmologists’ arsenal of DED products in Europe.”
“NovaTears as the first and only treatment specifically designed to treat evaporative DED provides high efficacy and great comfort to patients,” founder & chief innnovation officer Bernhard Günther added. “The therapeutic benefits of combining these qualities with those of Omega-3 fatty acids offer further advantages. I am confident that all dry eye patients will greatly benefit from this breakthrough innovation.”